Heart Failure
📧 Sign up to get email alerts when something new happens for Heart Failure.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2026-08-20FDA Approved: LISINOPRIL — Original Application (ANNORA PHARMA)
FDA approval overview for lisinopril original application by Annora Pharma.
-
FDA approval · 2026-07-23FDA Approved: FUROSCIX — Supplemental Application (scPharmaceuticals Inc., a wholly owned subsidiary of MannKind Corporation)
Supplemental application for FUROSCIX (furosemide injection 80 mg/10 mL) seeking approval for a new or expanded indication or formulation.
-
EMA approval · 2026-07-14EMA Authorised: Qaialdo (spironolactone) — Lipomed GmbH
EMA has authorized Qaialdo, a spironolactone product by Lipomed GmbH, for several conditions including edema, heart failure, liver cirrhosis…
-
EMA approval · 2026-06-11EMA Authorised: Forxiga (dapagliflozin propanediol monohydrate) — AstraZeneca AB
Forxiga (dapagliflozin propanediol monohydrate) has been authorised for use in the European Medicines Agency, with indications including Typ…
-
EMA approval · 2026-04-22EMA Authorised: Forxiga (dapagliflozin propanediol monohydrate) — AstraZeneca AB
EMA authorised Forxiga (dapagliflozin propanediol monohydrate) for type 2 diabetes mellitus, heart failure (systolic), and chronic kidney di…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-04-21EMA Authorised: Verquvo (vericiguat) — Bayer AG
EMA authorised Verquvo (vericiguat) from Bayer AG for the treatment of heart failure. This marks EU marketing authorisation for the medicine…
-
FDA approval · 2026-04-21FDA Approved: VALSARTAN — Original Application (Laurus Labs Limited)
FDA approved Laurus Labs Limited's original application for VALSARTAN (valsartan) as a generic product.
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approves Lupin's original application for dapagliflozin tablets (generic), enabling market entry for the SGLT2 inhibitor.
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Cipla USA Inc.)
FDA approved Cipla USA Inc.'s generic dapagliflozin (ANDA 211535) as an original application. The approval makes a generic version of dapagl…
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Ascend Laboratories, LLC)
FDA approved the original generic application for dapagliflozin, enabling a generic version of the SGLT2 inhibitor used for type 2 diabetes …
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Sandoz Inc)
FDA approves Sandoz's generic dapagliflozin under Original Application. The approval makes a generic version available for the same indicati…
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Florida Pharmaceutical Products, LLC)
FDA approved the Original Application (ANDA) for dapagliflozin from Florida Pharmaceutical Products, LLC.
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Macleods Pharmaceuticals Limited)
FDA approves the generic dapagliflozin from Macleods Pharmaceuticals Limited under an Original Abbreviated New Drug Application (ANDA).
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals Limited's original ANDA for dapagliflozin, enabling a generic version of the diabetes medication to rea…
-
EMA approval · 2026-03-24EMA Authorised: Jardiance (empagliflozin) — Boehringer Ingelheim International GmbH
EMA authorised Jardiance (empagliflozin) in the European Union for type 2 diabetes mellitus, heart failure, and chronic kidney disease, unde…
-
EMA approval · 2026-03-24EMA Authorised: Qaialdo (spironolactone) — Lipomed GmbH
Qaialdo is a spironolactone product by Lipomed GmbH that has been authorized in the EU. Indications include edema, heart failure, liver cirr…
-
EMA approval · 2026-03-13EMA Authorised: Edistride (dapagliflozin propanediol monohydrate) — AstraZeneca AB
The European Medicines Agency authorised Edistride, a dapagliflozin propanediol monohydrate medicine by AstraZeneca, for type 2 diabetes mel…
-
FDA approval · 2026-02-18FDA Approved: ARBLI — Supplemental Application (Scienture LLC)
FDA approved a supplemental application for ARBLI (losartan potassium) filed by Scienture LLC.
-
FDA approval · 2026-02-09FDA Approved: DIGOXIN — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approved a supplemental application for Digoxin submitted by Amneal Pharmaceuticals of New York LLC.
-
FDA approval · 2026-02-05FDA Approved: BUMETANIDE — Original Application (Novadoz Pharmaceuticals LLC)
FDA approves the original application for bumetanide (generic) from Novadoz Pharmaceuticals LLC, a loop diuretic indicated for edema associa…
-
EMA approval · 2026-01-26EMA Authorised: Dapagliflozin Viatris (dapagliflozin) — Viatris Limited
EMA authorised Dapagliflozin Viatris for type 2 diabetes mellitus, heart failure, and chronic kidney disease, with Viatris Limited as the ma…
-
FDA approval · 2026-01-20FDA Approved: SACUBITRIL AND VALSARTAN — Original Application (Somerset Therapeutics, LLC)
The FDA approved Somerset Therapeutics' original ANDA for a generic sacubitril/valsartan product, enabling a non-brand version of this heart…
-
EMA approval · 2026-01-13EMA Authorised: Neparvis (sacubitril;valsartan) — Novartis Europharm Limited
Neparvis, a sacubitril/valsartan combination, has been authorised by the EMA for heart failure. The marketing authorization holder is Novart…
-
EMA approval · 2026-01-13EMA Authorised: Entresto (sacubitril;valsartan) — Novartis Europharm Limited
The EMA authorised Entresto (sacubitril/valsartan) for heart failure in the European Union. The Marketing Authorization Holder is Novartis E…
-
FDA approval · 2026-01-08FDA Approved: FUROSEMIDE — Original Application (Micro Labs Limited)
FDA approved the original application for furosemide from Micro Labs Limited.